Business Wire

ees Europe: Battery Storage – Powerbanks for the Energy Transition

Share

Battery storage is booming. According to a study by Frontier Economics, the volume of grid-connected storage in Germany alone could increase to 60 gigawatts (GW) or 271 gigawatt-hours (GWh) by 2050. This is forty times the current storage capacity. Similar dynamics in cost reduction and installation speed are expected as seen with photovoltaics (PV) in recent years. Soon, battery storage will fundamentally change energy supply. The latest technologies, trends, and market developments will be showcased at ees Europe, Europe’s largest and most international exhibition for batteries and energy storage systems. It will take place from June 19 to 21 as part of The smarter E Europe, Europe’s largest alliance of exhibitions for the energy industry, in Munich. Around 3,000 exhibitors and over 115,000 visitors from around the world are expected in 19 exhibition halls and an outdoor area.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240604806032/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Innovations in the field of large-scale storage can be seen at this year’s ees Europe. (Photo: Business Wire)

The growth of grid-connected storage brings enormous advantages to the energy system and offers economic benefits. The expansion of large-scale storage can significantly reduce the need for new gas power plant investments in Germany by up to 9 GW. This expansion also contributes significantly to reducing CO2 emissions. The key point: this growth is purely market-driven and does not rely on government subsidies.

Short-term storage enables system transformation

Battery storage increasingly assumes critical roles in ensuring a reliable power supply and stabilizing power grids. Large battery storage systems ensure voltage control, provide immediate reserve capacity, and facilitate black start capability, playing a part in congestion management. They can balance fluctuations in the grid within seconds and store energy for hours or days. The black start capability of storage systems is crucial in emergencies.

Moreover, storage systems can mitigate the effects of delayed grid expansion. They help optimize the utilization of the limited grid infrastructure, allowing more facilities to be connected. This enables more capacity and additional PV installations despite limited grid connection capacity. Another benefit: battery storage increases the market value of renewable energy. Green electricity can be stored when market prices are low and fed into the grid when demand is high and electricity prices are correspondingly high.

International storage revolution

Worldwide, exponential growth in battery storage is evident. Experts predict that global production capacity will rise to 500 GWh per year by 2025. In markets such as Australia, the USA, and India, tenders for new wind or solar capacities have been coupled with storage for years. In Germany, the speed of expansion and the installed storage capacity are still modest. However, this year, battery storage systems in Germany will surpass pumped storage systems in installed capacity for the first time.

Setting the right framework

To make stationary storage of all sizes attractive, a favorable market environment and simple regulations are needed. Market-driven expansion must continue to be enabled and improved. Modern framework conditions for battery storage should be set through reforms in grid fees, flexible electricity tariffs, or the introduction of contracts for difference.

ees Europe

Every year, ees Europe, Europe’s largest and most international exhibition for batteries and energy storage systems, provides a networking opportunity for the industry’s key players – all under the motto “Innovating Energy Storage”. It focuses on the latest technologies, trends and market developments. ees Europe will take place from June 19–21, 2024 as part of The smarter E Europe at Messe München.

For more information: www.ees-europe.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

ressourcenmangel an der Panke GmbH
Roberto Freiberger
roberto.freiberger@ressourcenmangel.de

Solar Promotion GmbH
Peggy Zilay
zilay@solarpromotion.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

PMC Biogenix Announces Expansion and Restructure21.6.2024 23:00:00 CEST | Press release

PMC Biogenix, the leading sustainable producer of specialty fatty amides and high-value biobased products, announces the construction and expansion of its new Armoslip® facility in Gyeongju, South Korea allowing for a production capacity increase of 50%. Construction will begin late 2024 with new supply available by mid-2026. “We are excited to announce plans to build a new facility in Gyeongju. This investment will allow us to significantly increase production capacity to meet growing customer demand for our Armoslip products,” said Debtosh Chakrabarti, President, PMC Group N.A., Inc. Adding, “This project solidifies our commitment as the industry leader, delivering products and solutions to our customers, as well as to the local Gyeongju community. We appreciate the continued support of the Gyeongju, South Korea local government, community, and our customers.” As part of PMC’s ongoing commitment of ensuring long-term sustainability and success of the Biogenix business world-wide, a c

Esri Technology Used By ALS Therapy Development Institute to Map Clinical Trials21.6.2024 22:58:00 CEST | Press release

The ALS Therapy Development Institute (ALS TDI), a nonprofit biotech dedicated to ending amyotrophic lateral sclerosis (ALS), has used mapping technology from Esri, the global leader in location intelligence, to develop the ALS Trial Navigator. The new tool is designed to simplify and streamline the process by which people with ALS and their caretakers learn about current ALS studies. With the ALS Trial Navigator users can now explore an interactive map to find locations where applicable clinical trials are taking place. They can also receive a customized map based on their preferences and status of their ALS. "ALS Trial Navigator helps people living with ALS, those that might face it in the future, and researchers looking to enroll trials by educating the community and providing information about current studies all around the world," said Dr. Nadia Sethi, ALS TDI's director of community engagement, who oversaw the Navigator's design and creation. Once a person is diagnosed with ALS,

Lifezone Metals Announces Voting Results from its 2024 Annual General Meeting21.6.2024 22:30:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) announces the results of voting by shareholders at its 2024 Annual General Meeting (the “AGM”) held today in the Isle of Man. The ordinary resolutions below were passed by shareholders, with voting results as follows: Ordinary Resolutions For % For Against % Against Abstain % Abstain To receive the Company’s accounts for the financial year ended December 31, 2023 60,456,134 100.00% 0 0.00% 264 0.00% To re-elect John Dowd as a Class I Director of the Company 60,375,930 99.87% 79,177 0.13% 1,291 0.00% To re-elect Govind Friedland as a Class I Director of the Company 59,713,208 98.77% 79,319 0.13% 663,871 1.10% To re-elect Ambassador Mwanaidi Maajar as a Class I Director of the Company 60,314,469 99.77% 81,886 0.14% 60,043 0.10% A total of 60,456,398 or 75.57% of Lifezone Metals Ordinary Shares outstanding were represented at the AGM. If you would like to sign up for Lifezone Metals news alerts, please register here. About Lifezone Metals At Lifezone Me

Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer21.6.2024 22:00:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved FRUZAQLA (fruquintinib) as a monotherapy indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents, and who have progressed on or are intolerant to treatment with either trifluridine-tipiracil or regorafenib. The decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on April 25, 2024, and approval by the U.S. Food and Drug Administration (FDA) for adults with mCRC who have been previously treated with oxaliplatin- and irinotecan-based regimens on November 8, 2023.1,2 “People living with metastatic colorectal cancer face numerous difficulties, stemming both from their illness and the adverse effects of therapies. Given the complex nature of the d

Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions21.6.2024 21:45:00 CEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today presented new data from its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). These updated data on 12 patients who received the full dose as a single infusion in Parts B and C of the trial are consistent with previously reported positive results in the VX-880 trial and reinforce the transformative potential of this therapy. At baseline, all patients in the study had undetectable fasting C-peptide (a marker of endogenous insulin secretion), a history of recurrent SHEs in the year prior to screening, and required an average of 39.3 (min, max; 19.8, 52.0) units of insulin per day. Following a single infusion of VX-880 at the full dose, all 12 patients demonstrated islet cell engraftment and glucose-responsive insulin production by Day 90. At the latest visi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye